Smartwatch AI may predict liver crisis before symptoms start
NCT ID NCT07721454
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study tests whether an Apple Watch, combined with artificial intelligence, can detect early signs of improvement or deterioration in people with advanced chronic liver disease (cirrhosis). Participants wear the watch to continuously track heart rate, oxygen levels, sleep, activity, and other health signals. The goal is to see if these data patterns can predict a patient's clinical course and ultimately help guide care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Apple Watch (wearable device) paired with artificial-intelligence analysis
- What this could lead to
- If it works, this could point toward a non-invasive way to catch early signs of liver-disease worsening, potentially improving care and quality of life.
- What could go wrong
- This is a very small, early feasibility study with only 8 participants. The AI analysis may not prove accurate or generalizable, and wearing a smartwatch may not be practical for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
8 people
The number who actually took part.
- Started
-
Dec 2022
- Finished
-
Jan 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients hospitalized at Ente Ospedaliero Cantonale (EOC) in Lugano or Bellinzona or patients followed at the Department for Gastroenterology and Hepatology, Ente Ospedaliero Cantonale will be assessed for inclusion in the study
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 18-75 years * Diagnosis of advanced chronic liver disease (ACLD). * Either: * hospitalized for hepatic decompensation or acute-on-chronic liver failure (ACLF), including ascites, hepatorenal syndrome, hepatic encephalopathy, bacterial infection, gastrointestinal bleeding, or jaundice; or * outpatient with Child-Pugh B cirrhosis and no evidence of hepatic decompensation or ACLF at enrolment. * Willing and able to provide written informed consent. Exclusion Criteria: * Inability or refusal to provide written informed consent * Inability to wear or correctly use the Apple Watch * Patients with hepatocellular carcinoma beyond the Milan Criteria (one lesion up to 5 cm or 3 lesions up to 3 cm in diameter) * Presence of hepatic decompensation or ACLF
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advance chronic liver disease (ACLD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ente Ospedaliero Cantonale
Lugano, 6900, Switzerland